USB
61
11
CMG
67
3
MRK
27
5
HRL
41
2
HAL
60
2
AVY
50
2
ZTS
49
2
DLTR
38
4
XYL
45
8
LRCX
45
6
OI
42
5
TRV
56
3
AIV
70
2
PSA
56
5
HPE
61
6
CSX
57
6
AMG
52
2
F
47
4
KMI
69
2
O
22
2
USB
61
11
CMG
67
3
MRK
27
5
HRL
41
2
HAL
60
2
AVY
50
2
ZTS
49
2
DLTR
38
4
XYL
45
8
LRCX
45
6
OI
42
5
TRV
56
3
AIV
70
2
PSA
56
5
HPE
61
6
CSX
57
6
AMG
52
2
F
47
4
KMI
69
2
O
22
2
Financhill
Back

Cara Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
20

CARA
Cara Therapeutics

Last Price:
0.31
Seasonality Move:
-4.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Cara Therapeutics Price Quote

$0.31

Cara Therapeutics Key Stats

Sell
20
Cara Therapeutics (CARA) is a Sell
Day range:
$0.30 - $0.32
52-week range:
$0.24 - $1.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.95
P/B ratio:
24.05%
Volume:
172.1K
Avg. volume:
684.3K
1-year change:
-69.31%
Market cap:
$17M
Revenue:
$21M
EPS:
$-1.75

How Much Does Cara Therapeutics Make?

Is Cara Therapeutics Growing As A Company?

  • What Is Cara Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.47%
  • What Is Cara Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Cara Therapeutics Stock Price Performance

What Is Cara Therapeutics 52-Week High & Low?

Cara Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Cara Therapeutics?

  • How Much Debt Does Cara Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Cara Therapeutics Have?
    Cash and short term investments quarterly total is $42M
  • What Is Cara Therapeutics’s Book Value Per Share?
    Book value per share is 0.01

Is Cara Therapeutics Cash Flow Positive?

  • What Is CARA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$74.2M
  • What Is Cara Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $34.5M
  • What Is Cara Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $13.5M

Cara Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    CARA return on invested capital is -258.41%
  • What Is Cara Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -104.95%
  • What Is CARA Return On Equity?
    ROE is a measure of profitability and is -258.41%

Cara Therapeutics Earnings Date & Stock Price

Cara Therapeutics Competitors

  • Who Are Cara Therapeutics's Competitors?
    Below is a list of companies who compete with Cara Therapeutics or are related in some way:
    • Agilent Technologies Inc (A)
    • Citius Pharmaceuticals Inc (CTXR)
    • Moleculin Biotech Inc (MBRX)
    • NovaBay Pharmaceuticals Inc (NBY)

Cara Therapeutics Dividend Yield

Cara Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 51.81%
Revenue: -47.47% 58.14%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 1.66
Upside from Last Price: 433.87%

Major Shareholders

  • How many CARA shares are owned by institutional investors?
    27.3M CARA shares are owned by institutional investors
  • How many CARA shares are owned by insiders?
    3.1M CARA shares are owned by insiders